title: HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths.
authors.affiliation: Monash Health and Monash University, Melbourne, VIC, Australia. william.sievert@monash.edu.
authors.forename: William
authors.initials: W
authors.lastname: Sievert
authors.affiliation: Center for Disease Analysis, Louisville, Colorado, USA.
authors.forename: Homie
authors.initials: H
authors.lastname: Razavi
authors.affiliation: St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
authors.forename: Alexander
authors.initials: A
authors.lastname: Thompson
authors.affiliation: St George Hospital, Sydney, NSW, Australia.
authors.forename: Amany
authors.initials: A
authors.lastname: Zekry
authors.affiliation: Kirby Institute for Infection and Immunity in Society, Sydney, NSW, Australia.
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Dore
authors.affiliation: Alfred Hospital, Melbourne, VIC, Australia.
authors.forename: Stuart Keith
authors.initials: SK
authors.lastname: Roberts
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001315:Australia / Q000453:epidemiology; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000517:prevention & control / Q000821:virology; D006297:Health Services Accessibility; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008103:Liver Cirrhosis / Q000401:mortality / Q000517:prevention & control / Q000821:virology; D008113:Liver Neoplasms / Q000401:mortality / Q000517:prevention & control / Q000821:virology
chemical_list: D000998:Antiviral Agents